Minimally Invasive Aesthetic Treatment of the Face and Neck Using Combinations of a PCL-Based Collagen Stimulator, PLLA/PLGA Suspension Sutures, and Cross-Linked Hyaluronic Acid
Francisco de Melo,Alieksiéi Carrijo,Kyungkook Hong,Bruno Trumbic,Franco Vercesi,Heidi A Waldorf,Sabine Zenker
DOI: https://doi.org/10.2147/CCID.S248280
2020-05-05
Abstract:Francisco de Melo, 1 Alieksiéi Carrijo, 2 Kyungkook Hong, 3 Bruno Trumbic, 4 Franco Vercesi, 5 Heidi A Waldorf, 6 Sabine Zenker 7 1 Aesthetics International, Dubai, United Arab Emirates; 2 Clínica Carrijo, São Paulo, Brazil; 3 Hus-hu Dermatology Clinic, Seoul, South Korea; 4 Cap Evidence, Paris, France; 5 Aesthetic Surgery and Laser, Milan, Italy; 6 Waldorf Dermatology Aesthetics, Nanuet, NY, USA; 7 Dr Zenker Dermatology, Munich, Germany Correspondence: Francisco de Melo Tel +971 56 175 3929 Email franciscofmelo@gmail.com Background: Combinations of minimally invasive procedures (MIPs) are often used in aesthetic treatments and are increasingly considered as the new standard of care. Three agents with specific properties are available in this perspective: a polycaprolactone (PCL)-based collagen stimulator, a poly-L-lactic acid (PLLA)- and a poly-glycolic acid (PLGA)-based resorbable suspension suture with a 3D-cone technology, and a cross-linked hyaluronic acid (HA). Objective: To develop the first practice guidelines on rejuvenation treatment of the face and the neck using combinations of these agents, whether associated or not with other widely used MIPs such as botulinum neurotoxins or energy-based devices. Methods: A multi-disciplinary, multi-national board of plastic surgeons and dermatologists convened to develop guidelines using a predefined consensus method. The consensus was defined as ≥ 83% agreement rate between participants. Results: Practice guidelines and algorithms, describing optimal procedure sequence and spacing, are proposed for the treatment of upper-, mid-, lower-face and neck, combining the PCL collagen stimulator, the PLLA/PLGA suspension sutures, and the cross-linked HA, whether associated or not with other MIPs. Conclusion: These new guidelines provide general support to optimal management strategies. Individual treatment plans should be adapted according to the physician's individual competence and the patient's preferences. Keywords: botulinum toxins, combined modality therapy, dermal fillers, energy-based device, practice guideline, rejuvenation